Atossa Therapeutics Inc
(NAS:ATOS)
$
1.5
-0.12 (-7.41%)
Market Cap: 188.63 Mil
Enterprise Value: 124.20 Mil
PE Ratio: 0
PB Ratio: 2.34
GF Score: 41/100 Atossa Therapeutics Inc Webinar Transcript
Aug 15, 2020 / NTS GMT
John Heerdink
Tribe Public LLC - Analyst
Hi, Steven. Hi, Kyle.
Kyle Guse
Atossa Therapeutics, Inc. - CFO, General Counsel & Secretary
Hey, John.
Steven Quay
Atossa Therapeutics, Inc. - CEO & Chairman
Hey, John. How are you doing?
John Heerdink
Tribe Public LLC - Analyst
So welcome all to the Tribe Public webinar series event with Atossa Therapeutics today. We appreciate all of you that have already logged in and that will be logging in. And I'd like to introduce you to Dr. Steven Quay, M.D., Ph.D., Founder and CEO of Atossa Therapeutics, that's going to be giving us a presentation today on Atossa and their work across a couple of different fields, including COVID-19 as well as breast cancer.
And we also have the CFO of Atossa Therapeutics, Kyle Guse. Welcome, Kyle. And he is going to be helping out with a few of the slides in the presentation. And then we'll have a Q&A presentation -- a Q&A session at the end of the presentation. Please feel
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot